explore -WSS

explore

author：explore 2025-10-02 21:05:06 - browse：113

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： 2023 Nobel Prize in Medicine goes to Karikó and Weissman

WSS

Medicare drug price negotiation’s day in court

Novo Nordisk to expand supply of Wegovy for U.S. patients

The United States is paying nearly triple for new Covid vaccines

Flu, Covid vaccination rates decline, new survey data show

What we owe ALS patients — and why one company fell short

Vertigo drug brings hope for rare neuron disorder, Niemann

explore

explore

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

What will Novo Nordisk's VC do with its influx of cash?

Affirmative action in medical school literally saved lives

The stability of $0 premiums in Medicare Advantage

Hollywood unions extend contract negotiations for actors

Congress extends some pandemic preparedness programs

Heart attack and stroke risk calculators need revising

Apple Vision Pro: A first look at health apps on the new VR headset

Duchenne breakthrough therapy leaves behind pioneering families

Covid misinformation case heads to Supreme Court

knowledge

Congressmen charge Covid hearing ‘could have been an email’

What we need to know about Arena Bioworks

The real point of Kenneth Smith’s execution by nitrogen gas

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Nobel honors Karikó and Weissman's enduring partnership

ARCH Venture Partners is raising $3 billion for a life sciences fund

Wikipedia

focus

hotspot

leisure time